Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee

SOLENO THERAPEUTICS INC

Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.
Hahn received 10,046 RSUs vesting over 3 years under Outside Director Compensation Policy.
Hahn most recently was CFO of Verona Pharma through its acquisition by Merck for ~$10B in Oct 2025.
Previously CFO of Dova Pharma (acquired by Sobi for up to $915M) and Cempra (IPO lead).
Hahn brings nearly 30 years of CFO-level experience; certified CPA in Maryland and North Carolina.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.